Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Mar 13, 2023

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

Mar 13, 2023

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

Mar 8, 2023

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

Mar 8, 2023

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nov 14, 2022

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

Oct 12, 2022

ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

Sep 13, 2022

ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

Aug 15, 2022

ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

Aug 2, 2022

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

Jul 27, 2022

ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …26
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy